Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis (NASDAQ: CRIS) has announced the approval of inducement stock options for its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy. The grant, approved by the Board of Directors, allows Dr. Hamdy to purchase 200,000 shares of Curis common stock at an exercise price equal to the closing price on May 1, 2025.
The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting every three months thereafter, contingent on Dr. Hamdy's continued employment. The grant was made outside of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan as an inducement for Dr. Hamdy's employment.
Curis (NASDAQ: CRIS) ha annunciato l'approvazione di opzioni su azioni come incentivo per il suo nuovo Chief Medical Officer, Dr. Ahmed Hamdy. Il Consiglio di Amministrazione ha approvato la concessione che permette al Dr. Hamdy di acquistare 200.000 azioni ordinarie di Curis a un prezzo di esercizio pari al prezzo di chiusura del 1° maggio 2025.
Le opzioni hanno una durata di 10 anni e maturano in quattro anni, con il 25% che matura al primo anniversario e un ulteriore 6,25% ogni tre mesi successivi, subordinatamente alla permanenza del Dr. Hamdy in azienda. La concessione è stata effettuata al di fuori del Quinto Piano di Incentivi Azionari del 2010 di Curis come incentivo per l'assunzione del Dr. Hamdy.
Curis (NASDAQ: CRIS) ha anunciado la aprobación de opciones sobre acciones como incentivo para su nuevo Director Médico, Dr. Ahmed Hamdy. La Junta Directiva aprobó la concesión que permite al Dr. Hamdy comprar 200,000 acciones ordinarias de Curis a un precio de ejercicio igual al precio de cierre del 1 de mayo de 2025.
Las opciones tienen un plazo de 10 años y se consolidan durante cuatro años, con un 25% que se consolida en el primer aniversario y un adicional 6.25% cada tres meses posteriormente, condicionado a la continuidad laboral del Dr. Hamdy. La concesión se realizó fuera del Quinto Plan de Incentivos de Acciones Enmendado y Restablecido de 2010 de Curis como incentivo para la contratación del Dr. Hamdy.
Curis (NASDAQ: CRIS)는 새로 임명된 최고 의학 책임자 Dr. Ahmed Hamdy를 위한 유인 스톡 옵션 승인을 발표했습니다. 이 권한 부여는 이사회에서 승인되었으며, Dr. Hamdy가 2025년 5월 1일 종가를 기준으로 200,000주의 Curis 보통주를 매수할 수 있도록 합니다.
스톡 옵션은 10년 기간이며 4년에 걸쳐 베스팅되며, 첫 번째 기념일에 25%가 베스팅되고 이후 매 3개월마다 추가로 6.25%가 베스팅됩니다. 이는 Dr. Hamdy가 계속 고용되어 있는 경우에 한합니다. 이 권한 부여는 Dr. Hamdy 고용 유인을 위해 Curis의 2010년 개정 및 재확인된 제5차 주식 인센티브 계획 외부에서 이루어졌습니다.
Curis (NASDAQ: CRIS) a annoncé l'approbation d'options d'achat d'actions incitatives pour son nouveau directeur médical, Dr. Ahmed Hamdy. Le conseil d'administration a approuvé l'attribution permettant au Dr. Hamdy d'acheter 200 000 actions ordinaires de Curis au prix d'exercice égal au cours de clôture du 1er mai 2025.
Les options ont une durée de 10 ans et seront acquises sur quatre ans, avec 25% acquis à la première année et un supplément de 6,25% tous les trois mois ensuite, sous réserve que le Dr. Hamdy reste employé. Cette attribution a été effectuée en dehors du cinquième plan d'incitation aux actions amendé et restitué de 2010 de Curis, en tant qu'incitation à l'emploi du Dr. Hamdy.
Curis (NASDAQ: CRIS) hat die Genehmigung von Anreiz-Aktienoptionen für seinen neu ernannten Chief Medical Officer, Dr. Ahmed Hamdy, bekannt gegeben. Der Vorstand hat die Gewährung genehmigt, die Dr. Hamdy den Kauf von 200.000 Aktien der Curis-Stammaktien zu einem Ausübungspreis ermöglicht, der dem Schlusskurs vom 1. Mai 2025 entspricht.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre vesten, wobei 25% am ersten Jahrestag und anschließend alle drei Monate weitere 6,25% vesten, vorausgesetzt, Dr. Hamdy bleibt weiterhin im Unternehmen beschäftigt. Die Gewährung erfolgte außerhalb des fünften geänderten und neu gefassten Aktienanreizplans von 2010 von Curis als Anreiz für die Anstellung von Dr. Hamdy.
- None.
- None.
The Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock on May 1, 2025. The Inducement Grant has a 10 year term and vests over four years, with
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302447858.html
SOURCE Curis, Inc.
FAQ
Who is the new Chief Medical Officer of Curis (CRIS)?
How many stock options were granted to Curis's new CMO?
What is the vesting schedule for the CRIS stock options granted to Dr. Hamdy?
What is the expiration term of the stock options granted by Curis?
